- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02861209
Collaborative Network to Take Responsibility for Oral Anticancer Therapy (CONTACT)
CONTACT: A Prospective Interventional Multicentre Before-after Study for the Implementation of a Care Pathway to Increase Self-management of Patients With Cancer Who Are Treated With Oral Anticancer Medications
This study aims to develop, implement and evaluate a care pathway for patients with cancer who are treated with oral anticancer drugs (OACD).
The care pathway will be developed in six hospitals in Flanders, and will be adapted to the local setting and situation.
The investigators hypothesize that the implementation of a care pathway will increase the quality of the drug therapy, the communication between health care professionals (HCPs) and patients, and will lead to an improved level of self-management and adherence. Moreover, the invesitgators hypothesize that the care pathway will facilitate the communication between HCPs in the hospital setting and in ambulatory care, and will improve counseling skills, self-efficacy and self-confidence of HCPs.
At the end of the study, a roadmap for the nation-wide implementation of a similar care pathway will be constructed based on the experiences of the participating hospitals. This roadmap will certainly include an e-learning platform for healthcare professionals.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
For each hospital, an individual care pathway will be developed following the 7-phase model by Vanhaecht et al., 2011. This methodology aims to offer a systematic approach in 7 phases for the support of an interdisciplinary team in the development of new care pathways or in the improvement of existing ones.
The before-part of the study includes phases 1 to 4 that aim to map current practice in detail and to translate these findings into the development of a care pathway. Current practice will be investigated using mixed methods comprising:
- surveys evaluating care on the level of the hospital
- semi-structured interviews with healthcare professionals (HCP) and patients
- outcome assessments in patients included in the study (self-management, adherence, satisfaction with care, satisfaction with information, quality of life) using validated questionnaires at the start of the therapy, after 1 month and after three months
- outcome assessments in healthcare professionals at baseline (self-efficacy and perceptions on self-management) using validated questionnaires
- training and feedback sessions on counseling for HCPs
Based upon these findings, a care pathway in each hospital will be developed by a local project team of different stakeholders from different disciplines.
The after-part of the study includes phase 5-7 in which the care pathway is implemented, evaluated and continuously followed up.
Implementation and evaluation take place at the same time. The evaluation includes:
- outcome assessments in patients (newly recruited) at the start of the therapy, after 1 month and after three months
- outcome assessments in HCPs (follow up)
- evaluation of counseling skills
- focus group discussions and interviews with HCPs to evaluate the development and implementation of the care pathway.
At the end of the study a comparison of outcomes before and after the implementation will be made to study the impact of the care pathway on the before mentioned aspects (see "Brief Summary").
Type d'étude
Inscription (Anticipé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Antwerpen
-
Turnhout, Antwerpen, Belgique, 2300
- Recrutement
- Az Turnhout
-
Contact:
- Lise-Marie Kinnaer, PharmD
- Numéro de téléphone: 32 16328265
- E-mail: lisemarie.kinnaer@kuleuven.be
-
-
Oost-Vlaanderen
-
Ghent, Oost-Vlaanderen, Belgique, 9000
- Recrutement
- Maria Middelares Gent
-
Contact:
- Lise-Marie Kinnaer, PharmD
- Numéro de téléphone: 32 16328265
- E-mail: lisemarie.kinnaer@kuleuven.be
-
-
Vlaams-Brabant
-
Bonheiden, Vlaams-Brabant, Belgique, 2820
- Recrutement
- Imelda Bonheiden
-
Contact:
- Lise-Marie Kinnaer, PharmD
- Numéro de téléphone: 32 16328265
- E-mail: lisemarie.kinnaer@kuleuven.be
-
-
West-Vlaanderen
-
Kortrijk, West-Vlaanderen, Belgique, 8000
- Recrutement
- AZ Groeninge Kortrijk
-
Contact:
- Veerle Foulon, Prof. Dr.
- E-mail: veerle.foulon@kuleuven.be
-
Contact:
- Lise-Marie Kinnaer, PharmD
- Numéro de téléphone: 32 016328265
- E-mail: lisemarie.kinnaer@kuleuven.be
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- a hematological cancer of solid tumor
- starting an oral anticancer drug for the first time
- able to understand and speak Dutch
Exclusion Criteria:
- patients following an adjuvant oral anticancer therapy (e.g. tamoxifen)
- patients following a therapy with a study drug
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Aucune intervention: Non-care pathway
This arm comprises patients before the implementation of the care pathway. Patients starting with an oral anticancer therapy participate in the current care process. Outcomes are assessed at start of treatment, after 1 and after 3 months. The decision to start with an oral anticancer therapy depends solely on the treating physician. |
|
Expérimental: Care Pathway
This arm comprises patients after the implementation of the care pathway. Patients starting with an oral anticancer therapy in this arm, receive care as is described by the novel designed care pathway. Outcomes are again assessed at start of treatment, after 1 and after 3 months. The decision to start with an oral anticancer therapy depends solely on the treating physician. |
The care pathway will consist of procedures of care in the hospital (e.g.
consultations with doctors, contact moments with nurses, ...) that describe the initiation of an oral anticancer therapy and the further follow up.
The care pathway should describe how care can efficiently be organised.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Change in self-management skills
Délai: at the start of the therapy, after one and three months
|
There is no gold standard to define self-management. A definition from Barlow et al., 2002 (2) defines self-management as follows: the ability of an individual to manage the symptoms, treatment, physical and psychosocial consequences and life style changes due to his/her condition. Adequate self-management refers to the ability to monitor one's condition and to effect cognitive, behavioural and emotional responses necessary to maintain a satisfactory quality of life. The studied self-management skills in this project comprise "social integration and support", "health service navigation", "constructive attitudes and approaches", "skill and technique acquisition" and "emotional distress". |
at the start of the therapy, after one and three months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Change in medication Adherence
Délai: after one and three months of therapy
|
after one and three months of therapy
|
|
Change in patient satisfaction with treatment using the Cancer Therapy Satisfaction Questionnaire (CTSQ)
Délai: after one and three months
|
after one and three months
|
|
Change in patient satisfaction with care using Out-patsat 35
Délai: at the start of the therapy, after one and three months
|
The outpatsat is a questionnaire for ambulatory cancer patients in which they are asked to rate in different subscales their perceptions on care delivered by doctors, nurses and rate te overall organisation (accessibility of the hospital, ease of reaching the hospital by telephone, ...) during their stay at day hospital of consultations
|
at the start of the therapy, after one and three months
|
Health Related Quality of Life
Délai: at the start of the therapy, after one and three months
|
at the start of the therapy, after one and three months
|
|
Change in Distress using the Distress Barometer
Délai: at the start of the therapy, after one and three months
|
at the start of the therapy, after one and three months
|
|
Efficacy of treatment Using ECOG performance scale and RECIST criteria
Délai: at the start of the therapy, after one and three months
|
at the start of the therapy, after one and three months
|
|
Toxicity of treatment
Délai: at the start of the therapy, after one and three months
|
Summarizing adverse drug events
|
at the start of the therapy, after one and three months
|
Cost of care
Délai: at the start of the therapy, after one and three months
|
Prospective report on health care expenditures (use of healthcare and other services, use of medicines, …)
|
at the start of the therapy, after one and three months
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Change in Self-efficacy in HCPs using the Self-efficacy and Performance in Self-management Instrument (SEPSS)
Délai: at baseline (before the implementation of the care pathway) and after 24 months (during implementation)
|
SEPSS investigates the ability of a HCP to evaluate their own performance in daily practice and caregiving.
|
at baseline (before the implementation of the care pathway) and after 24 months (during implementation)
|
Change in perceptions on self-management in HCPs using the Clinician Support for Patient activation measure
Délai: at baseline (before the implementation of the care pathway) and after 24 months (during implementation)
|
at baseline (before the implementation of the care pathway) and after 24 months (during implementation)
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies du système digestif
- Tumeurs par type histologique
- Tumeurs
- Tumeurs par site
- Tumeurs gastro-intestinales
- Tumeurs du système digestif
- Maladies gastro-intestinales
- Tumeurs neuroectodermiques
- Tumeurs, cellules germinales et embryonnaires
- Tumeurs, tissu nerveux
- Maladies du côlon
- Maladies intestinales
- Tumeurs intestinales
- Maladies rectales
- Tumeurs neuroendocrines
- Nevi et mélanomes
- Tumeurs colorectales
- Mélanome
Autres numéros d'identification d'étude
- LMK15022016
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Implementation of a care pathway
-
University Health Network, TorontoAnemia Institute for Research & EducationComplétéCardiopathie | CoagulopathieCanada
-
University Hospital Southampton NHS Foundation...University of Southampton; South Central Ambulance service; Hampshire and Isle...Pas encore de recrutementCrise cardiaque | Réanimation cardiopulmonaire | Arrêt cardiaque hors de l'hôpitalRoyaume-Uni
-
University of StellenboschComplété
-
University of StellenboschComplétéVIH/SIDA | TB - Tuberculose | Thérapie antirétrovirale, hautement activeAfrique du Sud
-
Evolution Optiks LimitedComplétéAstigmatisme | Acuité visuelle | AnisométropieÉtats-Unis
-
Compedica IncProfessional Education and Research InstituteRecrutementUlcère du pied diabétiqueÉtats-Unis, Canada
-
National Institute of Allergy and Infectious Diseases...Institut National de la Santé Et de la Recherche Médicale, France; The Ministry... et autres collaborateursComplétéInfection par le virus EbolaÉtats-Unis, Guinée, Libéria, Sierra Leone
-
MRC/UVRI and LSHTM Uganda Research UnitKarolinska Institutet; Amsterdam Institute for Global Health and Development; University of Rwanda et autres collaborateursRecrutementVIH | Charge virale | Surveillance au point de serviceKenya, Ouganda
-
University of CalgaryHealth CanadaActif, ne recrute pas
-
Johns Hopkins UniversityPas encore de recrutement